Nima Kabir
Pulmonary Disease · Goldsboro, NCNPI 1467012898
Payments from drug & device makers
Across 82 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$359
- Actelion Pharmaceuticals US, Inc.$119
- Jazz Pharmaceuticals Inc.$116
- Grifols USA, LLC$110
- Sanofi$92
- Amgen$82
- plus $927 from 22 others
What the payments were for
- Food & beverage$1,72696%
- Education$794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $359 |
| Actelion Pharmaceuticals US, Inc. | 2 | $119 |
| Jazz Pharmaceuticals Inc. | 7 | $116 |
| Grifols USA, LLC | 4 | $110 |
| Sanofi | 4 | $92 |
| Amgen | 5 | $82 |
| Insmed, Inc. | 3 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $71 |
| Boehringer Ingelheim | 3 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| GSK | 3 | $50 |
| United Therapeutics Corporation | 2 | $49 |
| Harmony Biosciences LLC | 2 | $47 |
| Viatris Specialty LLC | 3 | $47 |
| Aucta Pharmaceuticals, Inc. | 3 | $45 |
| Verona Pharma, Inc. | 2 | $42 |
| Neurelis, Inc. | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| AbbVie | 2 | $38 |
| Merck | 1 | $36 |
| Ambu Inc. | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $32 |
| Abiomed | 1 | $31 |
| Lilly USA, LLC | 2 | $29 |
| TG Therapeutics, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $17 |
| Philips North America LLC | 1 | $16 |
How this compares
$1,805 in reported general payments places this provider in the 50th percentile of 393 pulmonary disease providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,797 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,449 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $50 | $9,79715 claims |
| AstraZenecaBreztri Aerosphere | $359 | $7,44912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Goldsboro
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
- Lake MorrisonDurham$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.